AbbVie Beats Forecast as Humira Sales Surge
Published: Oct 28, 2013
AbbVie Inc (ABBV.N) on Friday reported stronger-than-expected results for the third quarter, as booming sales of its Humira arthritis treatment and Synthroid thyroid replacement drug more than offset lower demand for other medicines. Shares of the drugmaker, which was split off at the beginning of the year from Abbott Laboratories Inc (ABT.N), rose 2.4 percent. Humira, a treatment for rheumatoid arthritis, psoriasis, Crohn's disease and other conditions, is the world's top-selling prescription drug.
Help employers find you! Check out all the jobs and post your resume.